Unusual case of residual cortical lens matter in anterior chamber

Modern cataract surgery does not allow for any residual cortical matter in the anterior or posterior chamber, not even in the capsular bag. But for a beginner, a residual cortex in the eye is preferable to a ruptured posterior capsule and its associated complications. Therefore, the surgeon can stop and allow a minor complication (retained cortical material) to prevent posterior capsular rupture.

Case report

A 52 year old female patient was operated for posterior subcapsular cataract in her right eye. Her left eye had previously gone into phthisis bulbi 5 years earlier; she underwent a 360° buckling with vitreoretinal surgery in her left eye for traumatic total retinal detachment 6 years earlier.

The surgery was performed by a resident eye surgeon who was in the learning stage of phacoemulsification. During cortical aspiration, the matter at the 12 o’clock position was proving difficult to handle for the surgeon. The surgeon therefore thought, in the best interest of the patient, that the amount of sub-incisional cortical matter (approximately 2 clock hours, extending up to the capsulohexis margin towards the centre) would absorb over time. He did not take the risk of further manipulations and getting a posterior capsular tear.

The surgeon increased the size of the corneal incision and implanted the all-PMMMA (Single-piece, Biconvex, Mod C Step Vault, from Al Optics Ltd, India) intraocular lens. (The patient could not afford any other lens and the above lens is available free of cost for deserving patients in our centre.) The wound was closed with 10/0 monofilament Nylon sutures.

The first postoperative day did not reveal any unusual inflammation. The eye was quiet on third postoperative day (first follow up). At second follow up (10th postoperative day), the operated eye revealed a white, fluffy mass (Fig 1) in the anterior chamber. This cotton-wool ball-like mass was diagnosed to be retained sub-incisional cortical lens matter based on normal anterior segment and fundus findings. The IOP was 28 mm Hg in her right eye. Because of the raised IOP and the one eyed status of the patient, immediate removal of cortical lens matter was planned. The side port was used to aspirate cortical matter with topical 0.5% oxybuprocaine (proparacaine) eye drops, using a 23 gauge canula. Postoperatively there was normalisation (off oral medications) of raised IOP within 48 hours. All sutures were removed after 6 weeks (Fig 2). The final best corrected visual acuity was 6/6.

Comment

The case is reported to highlight the importance of complete removal of cortical matter. The reason for difficulty in aspirating sub-incisional cortex in our case was inferiorly decentralised capsulohexis and corneal oedema at the incision site. Other reasons that can hamper the removal of such cortex could be positive vitreous pressure, long tunnel, fluid leakage due to divarication of incision lips, small capsulohexis, probable miosis and corneal folds. The raised IOP in our case could be due to obstruction of trabecular meshwork by lens debriss and inflammatory components in the form of heavy-molecular-weight soluble lens proteins. In: Phacoemulsification: principles and technique. Thorofare, NJ: Slack Inc, 1998:178.

Poster segment complications of graft versus host disease after bone marrow transplantation

The efficacy of bone marrow transplantation (BMT) for the treatment of selected diseases of the haemo poetic system such as chronic myeloid leukaemia (CML) is well recognised. Graft versus host disease (GVHD) is however a common and potentially life threatening complication of this treatment, occurring in up to 75% of cases. It is thought to arise when immunocompetent donor T lymphocytes mounted an immune response against host tissues. GVHD is characterised by a triad of enteritis, dermatitis, and hepatitis, but almost all organs may be targeted. Ocular involvement is frequently seen but is usually limited to the anterior segment. Posterior segment manifestations are rare.

This report describes two cases of GVHD with unusual posterior segment involvement that highlight the diversity of presentations in this condition.

Case 1

A 45 year old white male presented with progressive bilateral blurred vision and floaters 10 months post-BMT for CML. He had no history of ocular disease. His symptoms started 10 days after discontinuation of cyclosporin A as a routine protocol and were accompanied by alopecia, poliosis, vitiligo, and oral mucositis. A presumptive diagnosis of acute GVHD was made and cyclosporin restarted together with prednisolone. His other medications were azathioprine, aciclovir, fluconazole, and ranitidine.

Best corrected visual acuity was 6/9 bilaterally, with no afferent pupillary defect. There was no evidence of inflammation in anterior segments or vitreous and normal intraocular pressures. There was mild disc pallor with swelling and surrounding radial choroidal folds and several pale subretinal perifoveal lesions on the left. Systemic examination revealed widespread patchy alopecia with poliosis, vitiligo of the arms, and mild oral mucositis. Fluorescein angiography showed mild dilatation of the disc capillaries and extensive focal leakage from the retinal pigment epithelium, but no evidence of cytokid macular oedema. Ultra-
sonography showed a thickened posterior sclera. Optical coherence topography (OCT) showed subretinal fluid bilaterally. Cerebral magnetic resonance imaging (MRI) and lumbar puncture revealed no abnormalities.

The clinical appearances were consistent with posterior scleritis together with a diffuse retinal pigment epitheliopathy. A reducing regimen of high dose steroids in combination with acetazolamide resulted in clinical improvement and visual stabilisation.

Case 2
A 31 year old white female underwent total body irradiation and BMT for γδ-T cell splenic lymphoma. One month later she developed acute GVHD related erosive enteropathy resulting in life threatening exsanguination. Following successful resuscitation (which precipitated admission to intensive care for 6 weeks), she noted blurred left eye vision and described difficulty in dark adaptation and differentiating between shades of grey; there was right strabismic amblyopia. The patient’s medication comprised aciclovir, cyclosporin, penicillin, propranolol, and lansoprazole.

Visual acuity was 6/18 and N14 with the right eye, and 6/12 and N5 with the left. Colour vision was normal and visual fields were full. There was no afferent pupillary defect. The anterior chambers and vitreous were quiet. The optic discs were normal. At both maculas (Fig 1), there were deep subretinal cream coloured spots and retinal thickening and OCT evidence of subretinal fluid without cystoid changes. Fluorescein angiography showed a few hyperfluorescent spots consistent with focal retinal pigment epithelium dysfunction. Electrodiagnostic tests identified diffuse rod dysfunction.

Since there was biochemical evidence of renal impairment, acetazolamide was considered to be contraindicated to treat the subretinal fluid. By 4 months, the best corrected visual acuities were 6/12 right; 6/6 left. Repeat electrophysiology was unchanged, however by ten months the full field electroretinograms had improved to normal limits.

Comment
GVHD is presumed to be caused by donor T lymphocytes recognising minor histocompatibility antigens on recipient tissues that are then subjected to CD8-T lymphocyte mediated attack. Commonly reported ocular manifestations include pseudomembranous conjunctivitis, keratoconjunctivitis sicca, corneal epitheliopathy, and cataract.

Posterior segment involvement is rare and includes cotton wool spots as well as central serous chorioretinopathy. In both of our cases, there seems to be a striking temporal association between the onset of visual symptoms and an adverse event in the course of the disease. In case 1, in whom the cessation of cyclosporin resulted in acute GVHD, the ocular findings were consistent with scleritis, a feature only once previously reported. Postmortem studies have demonstrated choroidal infiltrates in GVHD patients containing histiocyte-like large eosinophils and clinically these may be represented by the pale perifoveal lesions observed in the left eye. Subsequently this patient was shown to be HLA-DR4 positive, a finding common in individuals with Harada’s disease and frequently associated with chronic GVHD.

By contrast, the ocular findings in the second case were not a result of acute but a consequence of previous life threatening GVHD during which exsanguination occurred. While interruption of blood flow to the optic nerve or visual cortex can account for visual loss following extreme haemorrhage, retinal ischaemia has also been documented. The rod photoreceptor system appears most vulnerable, a feature consis-
tent with the electrophysiological findings in this case, and the patient’s difficulty with dark adaptation is in keeping with rod dysfunction. Of interest was the subsequent improvement in acuity and electrophysiological responses. Such a pattern parallels electrophysiological studies of children after respiratory or circulatory arrest where initially subnormal ERG responses return to normal levels within 8 months.9 The mechanism that mediates this recovery is not known.

Graft versus host disease is a common complication of bone marrow transplantation that usually presents to the ophthalmologist with anterior segment signs. However, GVHD may also present with posterior segment presentations of the types described here.

N G Strouthidis, P J Francis, M R Stanford, E M Graham
The Medical Eye Unit, 9th Floor, North Wing, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7EH, UK

N G Strouthidis, P J Francis, G E Holder, A C Bird
Moorfields Eye Hospital, 162 City Road, London ECTV 2PD, UK

Correspondence to: Dr E M Graham, The Medical Eye Unit, 9th Floor, North Wing, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7EH, UK; nicholas.strouthidis@btinternet.com

Accepted for publication 25 February 2003

References


Anterior pathway vision loss due to subdural haematoma

Patients with vision loss associated with subdural haematomas typically present with homonymous hemianopias secondary to compression of the posterior cerebral artery during trans-tentorial herniation.12 In these cases, necropsy studies have demonstrated pregeniculate involvement in addition to occipital lobe lesions.2 We present a case illustrating a rarely reported phenomenon of anterior pathway vision loss associated with a subdural haematoma without any evidence of optic disc swelling, occipital lobe disease, or radiographic signs of chiasmal or optic nerve compression.

Case report

A 51 year old man, who had previously undergone two craniotomies (October 1992 and November 2000) for resection of an epidermoid tumour at the cerebellopontine angle, developed hydrocephalus and had a
null
severe atopic dermatitis (one) and traumatic cataract (one). The types of cataract included total/mature (seven), nuclear (two), lamellar (three), subcapsular (two), posterior lenticularis (two), and posterior polar (two).

All eyes underwent lens aspiration through can opener anterior capsulotomy or continuous curvilinear capsulorhexis (CCC) under general anaesthesia. Fourteen eyes had either posterior capsulotomy (with the vitrectomy cutter) or a posterior CCC (surgeon’s preference). Anterior vitrectomy was done in 13 eyes. Eleven eyes (61.1%) were implanted with a foldable intraocular lens (IOL) (Acrysof lens MA60BM, 10 and MA30BM, 1) (pseudophakic group) (Table 1). This group was older (mean 84.81 months) than the aphakic group (mean age 14.31 months). Only seven eyes (63.6%) of the pseudophakic group underwent posterior CCC/capsulotomy and anterior vitrectomy, compared to all eyes in the aphakic group. Complications were encountered in four eyes in the pseudophakic group (36.4%)—malposition of IOL, vitreous strand in AC, posterior synechiae and raised IOP.

Four eyes (two in the pseudophakic and two in the aphakic group) did not receive additional postoperative topical steroids (prednisolone acetate 1%). This decision was made for patients 4 and 12 as there was minimal manipulation and iris trauma intraoperatively. These children were older (ages 131 and 115 months at surgery), allowing for easier follow up examination. Patient 15 had developmental delay and was difficult to manage. All four eyes were assessed to be quiet by slit lamp examination 2–4 weeks postoperatively. Additional steroids were not indicated and there was no glaucoma or endophthalmitis.

One eye (patient 17) required adjuvant periocular dexamethasone (1 mg) for fibrous inflammation in the first week. The left eye of patient 6, which had been quiescent and without treatment for 2 months, developed raised IOP (30 mm Hg) at 3 months after surgery. This was controlled with topical betaxolol. There was no glaucomatous cupping and visual fields could not be performed in this young age of the child.

Patient 13 had severe atopic dermatitis requiring systemic prednisolone. When visually significant cataract developed in the left eye, preoperative prednisolone was increased prophylactically and a pellet of Surodex was inserted at the end of surgery. As there was minimal inflammation, the systemic steroid was tapered over 2 weeks and the steroid eye drops were stopped after 3 weeks. This eye achieved a final visual acuity of 20/20.

Table 1 Pseudophakic and aphakic groups

<table>
<thead>
<tr>
<th></th>
<th>Pseudophakic group</th>
<th>Aphakic group</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of eyes</td>
<td>11 (61.1%)</td>
<td>18 (73.9%)</td>
</tr>
<tr>
<td>Mean age at surgery</td>
<td>84.8 months</td>
<td>14.3 months</td>
</tr>
<tr>
<td>No. of eyes with posterior capsular opening and anterior vitrectomy</td>
<td>7 (63.6%)</td>
<td>7 (100%)</td>
</tr>
<tr>
<td>No. of eyes with intact posterior capsule</td>
<td>4 (36.4%)</td>
<td>0</td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraoperative complications</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Postoperative complications</td>
<td>4 (36.4%)</td>
<td>1 (14.3%)</td>
</tr>
<tr>
<td>1Malposition of PCIOL</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>2 Vitreous strand in anterior chamber with peaked pupil</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>3 Posterior synechiae</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4 Fibrous inflammation</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5 Raised intraocular pressure</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Comment

Fibrous anterior uveitis is common after paediatric cataract surgery, occurring in varying severities in up to 10% of cases. In our series, only two eyes (11.1%) developed inflammation that required additional steroid therapy. The remaining 16 eyes achieved good control of inflammation, particularly the four eyes that received Surodex without postoperative topical steroids. None experienced rebound uveitis after 1 week, when the pellet had ceased its release of dexamethasone. This suggests that in selected eyes, a Surodex pellet alone may be adequate to control postoperative inflammation. A randomised controlled trial comparing Surodex versus conventional steroid eye drop therapy will be needed to determine the ultimate efficacy of Surodex in paediatric eyes.

The efficacy of eye drops is dependent on compliance and timely application for drug penetration and absorption. In infants and young children, the systemic absorption of the steroid may have potentially serious complications such as hyperglycaemia and immunosuppression. Surodex significantly reduces the steroid dosage, as the 60 μg of dexamethasone in one pellet is approximately equivalent to that in just one drop of 0.1% dexamethasone. A system such as the DDS allows for direct application of the drug to the target site, potentially eliminating the problems of compliance.

The single complication encountered, which may be related to Surodex insertion, is the late onset of raised IOP (patient 6) despite the lack of marked postoperative inflammation. The fellow eye had also undergone cataract surgery with insertion of Surodex without complications. Steroid responsive glaucoma is an unlikely cause as the drug has been shown to persist only for 7 days in rabbits, although this has not been demonstrated in human eyes. Gonioscopy may reveal focal peripheral anterior synechiae (PAS) at the site of residual pellet, but it is unlikely that this minor degree of synechiae may cause angle closure glaucoma, although the pellet may persist for weeks in the angles. Unfortunately, gonioscopy was not performed in this eye. Glaucoma after paediatric cataract surgery is, however, a complication that increases in frequency with longer durations of follow up (3–22%).

We acknowledge that there are several limitations to these findings. Firstly, being a retrospective review, the efficacy of Surodex in preventing postoperative capsular opacification, an indicator of postoperative inflammation, could not be assessed. We are also unable to establish if Surodex alone is sufficient for postoperative control of inflammation, this would require a prospective randomised clinical controlled trial. The efficacy of control of postoperative inflammation and safety are incomplete without the assessment of flare and endothelial cell counts but these are difficult in children, although endothelial cell count studies in adult eyes have shown no significant change. Finally, gonioscopy to visualise the angles to look for PAS was also not done.

Surodex has previously been shown to be safe and effective in uncomplicated cataract surgery in adults. This retrospective review provides preliminary data to suggest that Surodex may be an effective and safe adjunctive anti-inflammatory agent that in some paediatric eyes may eliminate the need for other steroid administration. Further studies will be required to determine the ultimate safety of Surodex in paediatric eyes.

References


Correspondence to: Soon-Phah Chee, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751; chee_soon_phah@nec.com.sg

Accepted for publication 3 March 2003

The authors have no proprietary or financial interest in Oculex Pharmaceuticals, Inc, Sunnyvale, CA, or in the product Surodex.

Financial support: Nil.

Pars plana ciliary epithelial proliferation in 13q deletion syndrome

The 13q deletion syndrome is an uncommon chromosomal disorder affecting the long arm of chromosome 13 which is deleted to a variable degree. This syndrome is phenotypically characterised by mental retardation, structural malformations, facial dysmorphism, and a predisposition to develop retinoblastoma. In addition, children with 13q deletion syndrome also show optic nerve hypoplasia and retinal dysplasia. This intraocular tumour is diagnosed in approximately 80% of cases with this syndrome. Moreover, the incidence of bilateral retinoblastoma is much higher in individuals with this syndrome. The retinoblastoma susceptibility gene (RB-1), which gives rise to the neural retina, is located in band 13q14. The involvement of the q14 band on the long arm of chromosome 13 places patients with this syndrome at significant risk for developing retinoblastoma. In addition, children with 13q deletion syndrome also show optic nerve hypoplasia and retinal dysplasia. In this case, we report additional findings of pars plana ciliary epithelial proliferation in 13q deletion syndrome.

Case report

A 5 month old Hispanic female infant with a karyotype 46,XX, del (13) (q14.1q21.3) was referred to us for the evaluation of retinoblastoma. She had dysmorphic features, such as craniosynostosis. There was no family history of ocular or systemic disease. While under anesthesia, the patient’s right eye was examined, revealing a mass that occupied a large area of the inferior nasal portion of the retina, and extending into the vitreous cavity (Fig 1). It obscured the optic nerve head and was associated with retinal detachment. There were also fine vitreous seedlings. Ultrasonography disclosed a retinal tumour with intraretinal calcific foci. The preoperative diagnosis was retinoblastoma with vitreous seedlings, and she underwent enucleation of the globe. The left eye was unremarkable.

Macroscopic examination revealed a greyish-white tumour arising from the retina that exhibited calcific foci and was extended into the vitreous cavity. Histological examination of the tumour indicated a well differentiated retinoblastoma that displayed both Flexner-Wintersteiner and Homer-Wright rosettes (haematoxylin and eosin; original magnification ×200). Inset: note a large endophytic retinoblastoma arising from the inferior retina and obliterating the optic disc.

Comment

The extent of the deletions affecting the long arm of chromosome 13 may result in various developmental anomalies that constitute 13q syndrome. The retinoblastoma shows numerous Flexner-Wintersteiner and Homer-Wright rosettes (haematoxylin and eosin; original magnification ×200).

Figure 1

The retinoblastoma shows numerous Flexner-Wintersteiner and Homer-Wright rosettes (haematoxylin and eosin; original magnification ×200). Inset: note a large endophytic retinoblastoma arising from the inferior retina and obliterating the optic disc.

References


Phacoemulsification of posterior polar cataracts—a surgical challenge

Posterior polar cataracts are relatively uncommon yet they pose a significant chal-
enage to the cataract surgeon. Cataract surgery in these cases is frequently accompanied by a high incidence of posterior capsule rupture (PCR).

Morphology

Posterior polar cataracts are associated with remnants of the hyaloid system or the tunica vasculosa lentis.1 These cataracts may also occur without any relation to hyaloid remnants and appear as circular or rosette shaped opacities; they are hereditary and usually transmitted as a dominant trait. The gene for these has been mapped to chromosome 16q22.7

Classification

See Table 1 and Figure 1.

Methods

The incidence of posterior polar cataracts in our centre is approximately 3 per 1000. We conducted a retrospective review from 1994 to 1999 and identified 31 patients (36 eyes) who had surgery for posterior polar cataracts.

Results

Four eyes had PCR (11.1%) and the other 32 had uncomplicated surgery; 34 eyes achieved a best corrected visual acuity of 6/12 or better (94.4%).

Comment

Our series showed a PCR rate of 11.1% in contrast with the 26% incidence reported by Osher et al8 and 36% by Vasavada and Singh.9 No hydrodissection was attempted and only careful controlled hydrodelineation was performed. This was done using small aliquots of balance salt solution (BSS) to loosen the nucleus while simultaneously watching the capsular bag to ensure that the fluid wave passed gently. In some cases, no hydroprocedures were necessary as there was slow separation of the nucleus by the BSS flowing from the phaco tip.

Vasavada and Singh described the use of step by step chop in situ and lateral separation to minimise stress on the capsule-zonule complex.7 We preferred the use of the “lambda” technique which involved sculpting in the shape of the Greek letter (λ), followed by cracking along both “arms” and removal of the central piece first. The advantage of this is its gentleness in not stretching the capsule while removing the quadrants, especially the first one. We emphasise that this is our preferred technique and other techniques would be equally effective in skilled hands.

We also used low vacuum, low aspiration, and low inflow parameters to ensure a more stable anterior chamber; bottle height was at 50 cm, vacuum at 100 mmHg, and aspiration flow rate at 20 ml per minute. Optimum power setting was achieved when minimal movement of the nucleus occurred while sculpting.

The epinucleus and cortex were removed using manual dry aspiration with Simcoe cannula. This method is gentler as we believe that the aspiration pressure is more controllable with our “million dollar” hands. There is also no “after aspiration” effect which in the automated unit can continue for several milliseconds even after the foot has been taken off the pedal. The disadvantage of manual aspiration is the increased surgical time.

We also used low vacuum, low aspiration, and low inflow parameters to ensure a more stable anterior chamber; bottle height was at 50 cm, vacuum at 100 mmHg, and aspiration flow rate at 20 ml per minute. Optimum power setting was achieved when minimal movement of the nucleus occurred while sculpting.

The epinucleus and cortex were removed using manual dry aspiration with Simcoe cannula. This method is gentler as we believe that the aspiration pressure is more controllable with our “million dollar” hands. There is also no “after aspiration” effect which in the automated unit can continue for several milliseconds even after the foot has been taken off the pedal. The disadvantage of manual aspiration is the increased surgical time.

The status of the posterior capsule (PC) dictated the action of the surgeon. If the PC was absent or torn but with no vitreous loss, a dispersive viscoelastic was injected over the defect to tamponade and push the vitreous face backwards. A dispersive rather than a cohesive viscoelastic is preferable as it is more adapted to maintaining a space and stabilising the anterior vitreous face. If there was PCR with vitreous loss, a two port anterior vitrectomy was performed. Intracocular lens implantation in these cases would depend on the extent of the PCR and the integrity of the remaining PC.

Surgical management of posterior polar cataracts poses a special challenge to the cataract surgeon. It is important that the surgeon and the patient understand the technical difficulties associated and are aware of potential complications. It may be prudent to address these cases at the end of an operating list or to shorten the list in anticipation of prolonged surgical time. The surgeon should use a technique that he or she is most familiar and comfortable with. With emphasis on gentleness, together with patience and a well practised technique, the incidence of PCR can be minimised in phacoemulsification for posterior polar cataracts.

References

1 Luntz MH. Clinical types of cataracts. Duane’s Ophthalmology 1996;CD ROM

Molluscum contagiosum in an immune reconstituted AIDS patient

In spite of lower viral loads and increasing T cell counts, AIDS patients receiving highly active antiretroviral therapy (HAART) are not always successful in mounting an immune response to some opportunistic pathogens. In fact, CMV retinitis, which was known to occur in HIV patients with CD4 counts below 50 x 10^3/L, has been described in immune reconstituted patients with CD4 counts above 200 x 10^3/L.1 It is therefore important to make observations about the clinical spectrum of infectious disease in immune reconstituted AIDS patients. Here we report an isolated
CD4 count was 435, dropped to 15,000 and her CD4 count rose to 905,000. After 3 months of HAART with biopsy.

Intranuclear and intracytoplasmic inclusion bodies typical of molluscum contagiosum were noted (Fig 2). The lesion did not recur after fine needle aspiration cytology of the parotid gland. A diagnosis was made of epithelioid melanocytes positive for S100 and vimentin immunostains. Excision was deemed incomplete.

Comment

Immunocompetent patients with molluscum contagiosum involving the eyelid typically suffer from an isolated lesion that is self limited. Larger, more numerous and widespread molluscum contagiosum lesions have been documented in patients with AIDS, individuals immunosuppressed from using prednisone and methotrexate, or patients with lymphoreticular malignant neoplasms or sarcoidosis. In HIV infected individuals the disease runs a more protracted course with persistent lesions and there appears to be an inverse relation of the CD4 count and the number of molluscum contagiosum lesions. The present case shows that the patient’s reconstituted immune system from HAART can limit molluscum contagiosum infection to a single lesion at the eyelid, clinically and histologically identical to molluscum contagiosum lesions found in immunocompetent hosts. Such limited expression of molluscum contagiosum could be from a competent T cell response as noted in individuals with normal immune function or those with reconstituted immune response from HAART. Thus, clinically the presence of a solitary molluscum contagiosum lesion in an HIV infected individual suggests appropriate response to HAART.

References


Malignant melanoma of the conjunctiva metastasising to the parotid gland

Conjunctival melanoma is rare, accounting for just 2% of ocular malignancies. We present an unusual case of conjunctival melanoma with subsequent metastasis to the parotid gland. A diagnosis was made after fine needle aspiration cytology of the parotid gland was performed in light of the previous history.

Figure 1. Note solitary umbilicated lesion involving lower eyelid margin.

Figure 2. Histologically, the molluscum contagiosum shows intracellular eosinophilic inclusion bodies (haematoxylin and eosin ×120).

Figure 1. Pedunculated lesion arising from the nasal limbal conjunctiva, right eye.

Case report

A 79 year old white man presented to the eye clinic in September 1999. He had been noted 3 years previously to have a small inclusion cyst of the bulbar conjunctiva in his right eye, which he complained had increased in size and was becoming red and sore. Examination showed an inflamed pedunculated lesion 1 cm in diameter arising from the nasal limbal conjunctiva (Fig 1). The lesion was granulomatous and amelanotic. There was adjacent corneal opacity. Ocular examination was otherwise unremarkable.

The appearance of the lesion was felt to be unusual with a presumptive diagnosis of conjunctival malignancy. Excision biopsy with conjunctival autografting was performed.

Histology revealed a primary nodular malignant melanoma, at least 7 mm thick, composed of epithelioid sparsely pigmented melanocytes positive for S100 and vimentin immunostains. Excision was deemed incomplete.

The patient was referred for adjuvant treatment with cryotherapy. To date, there has been no sign of local recurrence.

In June 2001, the patient was referred by his general practitioner to the oral surgery service at the same hospital with a 6 month history of pain on the right side of his neck. He had also noticed some right facial swelling. Clinical examination disclosed a diffuse, firm mass over the lower pole of his right parotid gland, measuring 4 cm in diameter. There were no overlying skin changes.

Magnetic resonance imaging (MRI) of the head and neck showed a well defined lesion within the right parotid gland involving the deep lobe and the deeper portion of the
superficial lobe. A few small lymph nodes were visible at several sites bilaterally but none appeared enlarged. Computed tomography (CT) of the chest, abdomen and pelvis revealed single nodules measuring 3–5 mm at both lung bases, which may represent lung metastases.

An orthopantomogram was normal, and fine needle aspiration (FNA) cytology was performed. This showed scattered lymphocytes and highly pleomorphic non-lymphoid malignant cells, some containing flecks of pigment (Fig 2). While these appearances alone would not allow definitive diagnosis of melanoma, in the clinical context they were sufficient to conclude that the parotid swelling was likely to be metastatic melanoma. This was confirmed on subsequent parotid excision biopsy, which revealed extensive involvement of the parotid nodes and parotid parenchyma, extending into the external jugular vein.

Comment
Malignant melanoma is a relatively rare tumour in the parotid gland, with most tumours representing metastasis from cutaneous head and neck primaries. Very occasionally, as in this case, the primary tumour is non-cutaneous in origin.

 Conjunctival melanoma metastasising to the parotid has been noted in previous series, but remains rare. This case is unusual with respect to the initial size and appearance of the tumour, the previous history of a conjunctival cyst, and that definitive diagnosis of a metastatic lesion from a conjunctival primary was made by FNA. This method has been helpful in the diagnosis of other types of tumour in the parotid, and indeed in parotid melanomas of different origin. In this case, the patient’s previous ophthalmic history had been unknown to the maxillofacial surgeon management team, the case, and the diagnosis only became clear during reporting of the cytology, when the FNA findings could be compared with previous histology. This illustrates the importance of exhaustive history taking and the value of a cohesive local histopathology service.

F Cuthbertson
Department of Ophthalmology, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK

J Luck, S Rose
Royal United Hospital, Combe Park, Bath BA1 3NG, UK

Correspondence to: Dr Fiona Cuthbertson, Department of Ophthalmology, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK, fcuthbertson@hotmail.com

Accepted for publication 26 March 2003

References

Bilateral Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia

Aspergillus species are ubiquitous saprophytic moulds, commonly growing in soil, stored hay, and decaying vegetation. Even though exposure to Aspergillus is universal, infection in humans is uncommon. Aspergillus infection of ophthalmic interest usually causes keratitis or orbital cellulitis. Aspergillus endophthalmitis is a relatively rare condition that has a devastating course, with blindness as its usual outcome. The clinical diagnosis is difficult and the treatment is disappointing. In most cases, ocular involvement results from spread of aspergillosis infection from other organs and typically occurs in injecting drug users and in patients with immune deficiency of various causes. The leucopenia appears to be a predisposing condition for the occurrence of aspergillosis.

We report an unusual case of bilateral endogenous Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia in the absence of any detectable focus of aspergillosis infection elsewhere in the body and that showed a good response to specific systemic therapy.

Case report
A 51 year old white man with a previous diagnosis of chronic lymphocytic leukaemia and use of an immunosuppressive agent was referred to ophthalmological examination because of a red eye, pain, and blurred vision in his right eye. The clinical picture worsened and diagnosis of endophthalmitis was made. Intravitreous amphotericin B injection was performed and did not control the case. Culture of vitreous fluid was positive for Candida. This eye was eviscerated because of increasing pain, progressive infection, and poor response to treatment. Posterior histopathological study was conclusive for Aspergillus endophthalmitis in the right eye (Fig 1B and 2). At the same time, fundus examination of the left eye showed two subretinal exudative lesion located at nasal and inferior retina with retinal oedema associated with superficial haemorrhages (Fig 1A). The vitreous was clean and the central macula remained intact. Visual acuity was 6/6 in this eye.

Vitreous biopsy or culture may yield negative results in some cases of early intraocular Aspergillus endophthalmitis. We did not take a vitreous biopsy of the left eye, since we already had the diagnosis in the right eye and the visual acuity was 6/6. This eye was treated with intravenous amphotericin B and oral itraconazole with a good result. The patient remained stable with resolution of the lesions and no focus of systemic aspergillosis was found.

Comment
Fungal endophthalmitis is uncommon. In most of the cases Candida is the causal organism. Few cases of Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia have been described, and according to the literature endogenous Aspergillus endophthalmitis represents a manifestation of disseminated aspergillosis, usually a fatal infection. This case is unusual because it is bilateral and no focus of systemic aspergillosis was found.

The cases of intraocular inflammation secondary to Aspergillus are more common in the central macula and have a poor prognosis. In our case the localisation of the chorioretinitis in the left eye was out of the posterior area and the patient’s visual acuity remained 6/6.

The major antifungal agent used in aspergillosis is amphotericin B. Without host immune competence, treatment is rarely effective. Penetration of intravenous amphotericin B into the vitreous cavity of the normal or inflamed eye is poor. The azole compounds have been used to reduce the significant toxicity and enhance the efficacy.

of intravenous amphotericin B; oral fluconazole is the drug of choice because it has excellent penetration in central nervous system and vitreous. Itraconazole may be used. Intravitreal amphotericin B and vitrectomy have given the best results in the treatment of these cases. Our patient received intravenous amphotericin B and oral itraconazole and this therapy was sufficient to control the infection.

This case shows that Aspergillus endophthalmitis should be considered in all patients with immune deficiency even in the absence of systemic aspergillosis. Treatment with intravitreal amphotericin B may be able to control these cases and should be attempted more often.

D de O Machado, R Gonçalves, E M Fernandes, W R Campos, F Oréficé
Department of Ophthalmology, Federal University of Minas Gerais, Brazil

A L L Curi
Department of Ophthalmology, Federal Fluminense University Niterói, Brazil

Correspondence to: André L L Curi, R Francisco Dutra 163/701, Icaraí, Niterói, RJ, Brazil Cep 24220150; curiall@yahoo.com

References

Late bleb needling
Surgical manipulation of the trabeculectomy bleb has become a recognised postoperative procedure to increase the success of glaucoma surgery. The first needling revision of a glaucoma drainage bleb was described in 1941 and there are several reports of the successful restoration of failing blebs within the first 3 years following trabeculectomy.12

We report the results of five cases of late bleb needling with 5-fluorouracil (5-FU) where trabeculectomy had been performed between 8 and 30 years earlier.

Table 1 Demographic details of patients

<table>
<thead>
<tr>
<th>Case no</th>
<th>Drainage procedure</th>
<th>Delay to needling (years)</th>
<th>No of needlings</th>
<th>No of 5-FU injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Right trabeculectomy</td>
<td>6</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Left trabeculectomy</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>Right trabeculectomy</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>Right trabeculectomy</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>Bilateral trabeculectomy</td>
<td>12</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

ECCE = extracapsular cataract surgery.

Table 2 Results of pre-bleb and post-bleb needling with a 12 month follow up period

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Pre IOP (mm Hg)</th>
<th>Post IOP (mm Hg)</th>
<th>No of medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
<td>M</td>
<td>20</td>
<td>15</td>
<td>3 acetazolamide</td>
</tr>
<tr>
<td>2</td>
<td>70</td>
<td>F</td>
<td>25</td>
<td>10</td>
<td>2 acetazolamide</td>
</tr>
<tr>
<td>3</td>
<td>80</td>
<td>M</td>
<td>23</td>
<td>15</td>
<td>3 acetazolamide</td>
</tr>
</tbody>
</table>

Case reports
The demographic details of all cases are summarised in Table 1.

Glaucoma surgery had taken place between 8 and 31 years before bleb needling and in no case had antimetabolites been used at the original surgery. Before bleb needling the average intraocular pressure (IOP) among the patients was 29.4 mm Hg (range 19–58). Each patient showed glaucomatous deterioration despite being on maximum tolerated medical therapy, taking on average three ocular hypotensive agents, and in two cases oral acetazolamide. In all cases an open sclerotomy was confirmed by gonioscopy.

All procedures were performed in the outpatient clinic, by either a consultant or associate specialist, using a slit lamp. The eye was anaesthetised with amethocaine eye drops 1%, and phenylephrine eye drops 2.5% were used for vasoconstriction. After several drops of chloramphenicol the conjunctiva was entered several millimetres from the flap site with a 27 gauge needle mounted on an insulin syringe. In one case aqueous flow was established after perforating scar tissue around an encysted bleb, whereas in the others it was necessary to dissect beneath the scleral flap and enter the anterior chamber. After creating a bleb and confirming a reduction in IOP by applanation tonometry, 5 mg 5-FU (25 mg/ml) were injected into the subconjunctival space around the bleb. After needling, all hypotensive therapies were stopped and replaced by intensive topical steroids and chloramphenicol. The steroid was titrated, and repeat injections of 5-FU with or without needling were given, according to the IOP and appearance of the bleb. After 12 months’ follow up from the last needling (Table 2), average IOP was reduced to 14 mm Hg (range 9–17). There was no change in the patients’ visual acuity. Two cases developed a mild corneal epitheliopathy that healed within 8 weeks. There were no other complications from the needling procedure.

Comment
Although trabeculectomy is the preferred glaucoma drainage procedure, only 67% of patients may achieve an adequate target pressure after 1 year. In recent years glaucoma surgery has developed with the use of antimetabolites and intense postoperative surveillance with bleb manipulation. Reports show that bleb needling used in combination with subconjunctival 5-FU injections can rectify a failing bleb in the early postoperative phase but there are few reports confirming its effect in the late postoperative period. Some studies have indicated that the success of bleb needling is unrelated to the time lapse from the original surgery, though in these studies the maximum interim period was less than 4.5 years.

The patients presented in this study had their original glaucoma surgery at least 8 years previously and bleb needling was carried out before listing the patient for a repeat trabeculectomy with mitomycin C. The only adverse effect noted was a temporary corneal epitheliopathy, probably related to toxicity of the 5-FU. Other reported adverse events after bleb needling include hyphaema, bleb leak, shallow anterior chamber, choroidal effusion and endophthalmitis, but there are no reports of long term hypotony as has been described following mitomycin C trabeculectomy.

These case reports indicate that bleb needling may be successful in achieving a long lasting IOP reduction even several years after the original surgery. The procedure does not require dexterous skills beyond that of a trained general ophthalmologist. It appears at least as safe as trabeculectomy and avoids a formal operation. If it does fail the surgical field is still intact for a "redo" trabeculectomy.

C T Ung, H Von Lany, K G Claridge
Taunton and Somerset NHS Trust, Musgrove Park, Taunton TA1 5DA, UK
Thermochemotherapy in hereditary retinoblastoma

Schueler and associates describe their experience with thermochemotherapy (TCT) in bilateral retinoblastoma.¹ The reported results of transpupillary photocoagulation used in combination with chemotherapy are encouraging, with 86–96% tumour control.² In the current series, however, local recurrence occurred in 38%.

The dosage of carboplatin used in the current series was 10 mg/kg body weight, which is lower than the standard dosage of 18.6 mg/kg body weight.³ Lower dose of carboplatin, the key drug in the chemotherapeutic regimen for retinoblastoma, could have influenced the higher recurrence rate.

The authors mention that they treated submacular tumours with TCT. However, in our experience, tumours located in the macular area are better treated initially with chemotherapy for 3–6 cycles in order to achieve maximum possible reduction in tumour size before considering thermochemotherapy. Chemotherapy reduced tumour size and allowed for a more uniform coverage of the macula. A smaller scar thus produced may optimise residual central vision.

The high mean total duration of thermochemotherapy in the current series is probably because of a smaller spot size of 0.4 mm. The diode laser (Iris Medical Inc, Mountain View, CA, USA) with an operating microscope adapter allows for a spot size of 0.8, 1.2, and 2.0 mm.³ The relatively newer large spot indirect ophthalmoscope delivery system provides a 1.2 mm spot size.³ A larger spot size will indeed reduce the duration of thermochemotherapy and allow for a more uniform coverage. Corneal, iris, and lens complications are minimised with better convergent beam optical systems currently available.

We believe that with higher dose of carboplatin, staggered chemotherapy for submacular tumours, use of better optical systems for delivery and a larger spot size for thermochemotherapy, and judicious selection of cases, the tumour regression and vision salvage with TCT could be further optimised.

R Murthy, S G Honavar, M Naik, V A P Reddy
Ocular Oncology Service, LV Prasad Eye Institute, Hyderabad, India
Correspondence to: Santosh G Honavar, MD, Ocular Oncology Service, LV Prasad Eye Institute, LV Prasad Marg, Banjara Hills, Hyderabad 500 034, India; honavar@lvp.eye.aph.org

Accepted for publication 21 April 2003

References

An error occurred in the author listings for two letters in the September issue. In the letter by Lee et al (Br J Ophthalmol 2003;87:1184–5) the order should be D K Lee, E B Suhler, W Augustin, R R Buggage.

In the letter by Buggage et al (Br J Ophthalmol 2003;87:1190–1) the order should be R R Buggage, D G Callanan, D F Shen, C C Chen. The journal apologises for the error.

In the article by Williamson et al in the September issue (Br J Ophthalmol 2003;87:1126–9), the author list contained an error. The correct spelling is N Strothids. The journal apologises for the error.

In the article by Courtright et al in the September issue (Br J Ophthalmol 2003;87:1079–82), the author list contained an error. The correct spelling is A Hoochsmann. The journal apologises for the error.
Elaboration of avoidable blindness

The latest issue of *Community Eye Health* (No 46) discusses the resolution of the World Health assembly on the elimination of avoidable blindness. For further information please contact: Journal of Community Eye Health, International Resource Centre, International Centre for Eye Health, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Tel: +44 07990 793664; email: Anita.Shah@lshtm.ac.uk; website: www.jceh.co.uk. Annual subscription (4 issues) UK £28/US$45. Free to developing country applicants.

Second sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. Details can be found at the charity’s website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

Specific Eye Conditions (SPECS)

SPECS represents over 50 different organisations related to eye disorders ranging from conditions that are relatively common to very rare syndromes. The website acts as a portal giving direct access to support groups' own websites. The SPECS web page is a valuable resource for professionals and may also be of interest to people with a visual impairment or who are blind. For further details about SPECS, contact: Kay Parkinson, SPECS Development Officer (tel: +44 (0)1803 524238; email: k@eyeconditions.org.uk; website: www.eyeconditions.org.uk).

The British Retinitis Pigmentosa Society

The British Retinitis Pigmentosa Society (BRPS) was formed in 1975 to bring together people with retinitis pigmentosa and their families. The principle aims of BRPS are to raise funds to support the programme of medical research into an eventual cure for this hereditary disease, and through the BRPS welfare service, help members and their families cope with the everyday consequences caused by retinitis pigmentosa. Part of the welfare service is the telephone help line (+44 01280 860 363) for any queries relating to retinitis pigmentosa, especially for those recently diagnosed with retinitis pigmentosa (tel: +44 (0)1280 821 334; email: lynda@brps.demon.co.uk; website: www.brps.demon.co.uk).

Surgical Eye Expeditions International

Volunteer ophthalmologists in active surgical practice are needed to participate in short term, sight restoring eye surgery clinics throughout the world. Contact: Harry S Brown, Surgical Eye Expeditions International, 27 East De La Guerra, C-2, Santa Barbara, CA 93101-9858, USA (tel: +805 963 3303; fax: +805 965 3564; email: hsbrown.md@cox.net or seeintl@seeintl.org; website: www.seeintl.org).

Rise in organ transplant numbers

According to UK Transplant, the UK has seen the highest number of organ transplants in six years. Last year (1 April 2002 to 31 March 2003), 2777 patients had their lives saved or dramatically improved through the generosity of 1064 donors. This equated to a 6% increase compared to the previous 12 months (1 April 2001 to 31 March 2002). Furthermore, during 2002–3, the highest number of people benefited from eye transplant for five years (1997–98) and 240 more people had their sight restored than the previous year. For further information see UK Transplant’s website (www.uktransplant.org.uk).

Elaboration of avoidable blindness

The 56th World Health Assembly (WHA) considered the report on the elimination of avoidable blindness (doc A56/26) and urged Member States to: (1) Commit themselves to supporting the Global Initiative for the Elimination of Avoidable Blindness by setting up a national Vision 2020 plan by 2005; (2) Establish a national coordinating committee for Vision 2020, for a national blindness prevention committee to help implement the plan; (3) Implement the plan by 2007; (4) Include effective monitoring and evaluation of the plan with the aim of showing a reduction in the magnitude of avoidable blindness by 2010; (5) Support the mobilisation of resources for eliminating avoidable blindness. The WHA also urged the Director-General to maintain and strengthen WHO’s collaboration with Member States and the partners of the Global Initiative for the Elimination of Avoidable Blindness as well as aid in the coordination and support of national capacity.

Glaucoma Society 24th Annual Meeting and Dinner

The Glaucoma Society 24th Annual Meeting and Dinner will take place on 20 November 2003, from 8.30 am to 3.00 pm at The Royal College of Physicians, London, UK. Further details: Ms Janet Flowers (email: glausoc@ukeire.freeserve.co.uk).

Detachment course with international faculty on: retinal and vitreous surgery with case presentations preceding the annual meeting of Iranian Society of Ophthalmology

The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding the Annual Meeting of the Iranian Society of Ophthalmology will be held on 29–30 November 2003 and 1–4 December 2003 respectively, at the Razi Conference Center, Hemmat Hyw, Tehran, Iran. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleisschr. 12, Breuningerbau, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid. kreissig@med.uni-tuebingen.de). Local organisation: Dr Arman Masheyekhi, Dr Siamak Moradian, Dept of Ophthalmology, Labbanfinejad Medical Center, Pasdaran Ave, Boosan 9, Tehran, 16666, Iran (fax: +98 21 254 9039; email: labball@hotmail.com).

5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT)

The 5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) will take place 11–14 March 2004, in Monte Carlo, Monaco. Please visit our website for details of the scientific programme, registration, and accommodation. To receive a copy of the Call for Abstracts and registration brochure, please submit your name and email address to http://www.kenes.com/isopt/isopt.htm. Further details: ISOPT Secretariat (website: www.kenes.com/isopt).

XVth Meeting of the International Neuro-Ophthalmoology Society

The XVth Meeting of the International Neuro-Ophthalmoology Society (ISSO) will be held on 18–22 July 2004, in Geneva, Switzerland. Further details: Prof. A Safran, University Hospital Geneva, c/o SYMPORG SA, Geneva (fax: +41 22 839 8484; email: info@symorg.ch; website: www.symorg.ch).

4th International Congress on Autoimmunity

The 4th International Congress on Autoimmunity will take place 3–7 November 2004 in Budapest, Hungary. The deadline for the receipt of abstracts is 20 June 2004. Further details: Kones International Congress Organisers and Association Management Services, 17 Rue du Cendrier, PO Box 1726, CH-1211 Geneva 1, Switzerland (tel: +41 22 908 0488; fax: +41 22 732 2850; email: autoim04@kones.com; website: www. kones.com/autoim2004).

Wake up call as dream time deadline looms

Scientists have less than a month left to apply for a new Dream Time award from NESTA, the organisation that invests in UK creativity and innovation. Dream Time supports exceptional achievers (with at least 10 years experience in their field) who want time to experiment or follow a passion, but who intend to continue with their career and put what they have discovered to good use. Up to 12 exceptional individuals from the fields of science, technology and the arts will each receive up to £40,000 to pursue their goals and push at the boundaries of knowledge and practice. NESTA is looking for people who can demonstrate evidence of exceptional achievement. This would include a significant body of work collated over at least a decade in their field, the ability to work in new ways and a commitment to the proposed area of exploration. Dream Time is a development of NESTA’s existing Fellowship Programme, which has helped talented and creative individuals to innovate and explore new ideas emerging through periods of personal development. As with all its awards, NESTA is looking for people who demonstrate excellence, promise, creativity, innovation and commitment. Funding can be used on a full- or part-time basis, in tandem with professional careers or temporarily away from the constraints of employment. Offered awards can be for any period of time up to 12 months.
one year. Dream Time Fellows will be asked to provide 10% in kind support for their plan and will be required to plan ways of disseminating their findings with their professional community. To apply, visit NESTA’s website: www.nesta.org.uk/dreamtime.

14th Meeting of the EASD Eye Complication study group

The 14th Meeting of the EASD Eye Complication (EASDEC) study group will take place on the 21–23 May 2004. There will be key lecture notes on the following topics:

- Peter Gaede (Denmark)—Results of the Steno 2 study
- Hans Peter Hammes (Germany)—Animal models of diabetic retinopathy
- Massimo Porta (Italy)—Screening with the London protocols: 12 years after
- Anselm Kampik (Germany)—Surgical options in diabetic retinopathy

There will also be case presentations and oral and poster presentations. The EASDEC board comprises F Bandello (President), PJ Guillausseau (Vice President), C-D Agardh (Past President), P Massin (Secretary), M Porta (Treasurer). The Scientific and Organizing Committee includes: F Bandello, PJ Guillausseau, P Massin, C-D Agardh, M Porta, A Kampik, M Ulbig, and G Lang. There are three travel grants available, at 1000 Euro each, for young scientists (less than 35 years at the time of the meeting). Application for the grant should be made together with the submission of the abstract. For further information, contact: Department of Ophthalmology, Ingrid Mannl, Ludwig-Maximilians-University, Mathildenstr. 8, 80336 Munich, Germany (tel: +49-89-5160-3800; fax: +49 89 5160 4778; e-mail: easdec@ak-i.med.uni-muenchen.de. The deadline for abstracts is 2 March 2004.

www.bjophthalmol.com

For just $8 you can purchase the full text of individual articles using our secure online ordering service. You will have access to the full text of the relevant article for 48 hours during which time you may download and print the pdf file for personal use.

www.bjophthalmol.com